A U.K. study has uncovered distinctive genetic drivers of type 2 diabetes in South Asians that lead to faster development of complications, the need for earlier insulin replacement therapy and a weaker response to some widely prescribed drugs. That points to the need to refine care pathways. But in addition, the research provides a potent illustration of how the under-representation in genomics databases of people who are not of white European origin can skew results and be a source of discrimination. Read More
Researchers from Memorial Sloan Kettering Cancer Center and affiliated organizations revealed findings from the preclinical evaluation of 1H5, a novel monoclonal antibody (mAb) candidate that inhibits the NOTCH signaling pathway and is being developed for the treatment of high-grade gliomas (HGGs). Read More
Sunshine Biopharma Inc. has completed mouse model studies providing proof of concept for the company’s K1.1 mRNA product as a novel therapeutic agent for human hepatocellular carcinoma (HCC). Read More
Ipsen SA and Biomunex Pharmaceuticals SAS have signed an exclusive global licensing agreement for BMX-502, a preclinical novel T-cell engager with potential for solid tumors. BMX-502 is a bispecific antibody that engages and activates mucosal-associated invariant T (MAIT) cells and targets the GPC3 tumor antigen, to kill cancer cells. Read More
Alveogene Ltd. has announced its novel inhaled gene therapy for lethal neonatal surfactant protein B (SP-B) deficiency, AVG-002, has been awarded orphan drug designation by the FDA. Read More
Oncoc4 Inc. has obtained IND approval from the FDA for AI-081, a PD-1 and VEGF bispecific antibody for the treatment of advanced solid tumors. Read More
Genfit SA and its collaborators have described the preclinical efficacy of SRT-015, a liver-selective ASK1 inhibitor in models of liver failure. Read More
Ventus Therapeutics US Inc. patents describe new cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors potentially useful for the treatment of autoimmune disease, rheumatic diseases and liver diseases, among others. Read More
Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Congruence Therapeutics Inc. to generate novel small-molecule correctors against multiple protein targets in the oncology area. Read More
Amgen Inc. has reported new 5,6- and 6,6-fused bicyclic alcohols and ethers acting as 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitors. They are reported to be useful for the treatment of gastrointestinal disorders. Read More
Arcus Biosciences Inc. has synthesized new E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer. Read More
Clostridioides difficile is a gram-positive bacteria that causes disease in persons with dysbiosis of the gut microbiota and has been listed as an urgent threat due to the emergence of resistance. Read More
Researchers from Universita degli Studi di Pavia and Universita degli Studi di Torino have prepared and tested new boron-based compounds for the treatment of Alzheimer’s disease by capture-enhanced neutron irradiation (CENI). Read More
The reversible transition between glioblastoma tumor-initiating cells, also known as glioma stem cells (GSCs), and differentiated glioma cells due to epigenetic modifications is one of the challenges in the development of effective glioma treatments. Read More
TRAF2- and NCK-interacting kinase (TNIK) has been reported as a therapeutic target for colorectal cancer and, more recently, for lung squamous cell carcinoma, triple-negative breast cancer, or ovarian cancer, among others, especially in combination with inhibiting cancer-related kinases. Read More
